Johnson & Johnson (JNJ) Capital Expenditures (2009 - 2026)

Johnson & Johnson has disclosed Capital Expenditures across 18 years of filings, most recently posting $1.3 billion for Q2 2026.

• In Q2 2026, Capital Expenditures rose 26.65% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $5.4 billion (up 19.76% YoY), while the FY2025 annual figure was $4.8 billion, up 9.22% from the prior year.
• Capital Expenditures came in at $1.3 billion for Q2 2026 at Johnson & Johnson, up from $1.0 billion in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.8 billion in Q4 2025 to a low of $607.0 million in Q2 2022.
• Average Capital Expenditures over 5 years is $1.2 billion, with a median of $1.0 billion recorded in 2025.
• Year-over-year, Capital Expenditures surged 42.17% in 2023 and retreated 13.17% in 2024.
• Over 5 years, Capital Expenditures stood at $607.0 million in 2022, then jumped by 161.78% to $1.6 billion in 2023, then rose by 1.45% to $1.6 billion in 2024, then rose by 13.96% to $1.8 billion in 2025, then dropped by 28.09% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1.3 billion in Q2 2026, $1.0 billion in Q1 2026, and $1.8 billion in Q4 2025.